title: Denileukin diftitox for the treatment of cutaneous T-cell lymphoma.
abstract: Cutaneous T-cell lymphoma/mycosis fungoides (CTCL/MF) is a rare lymphoproliferative disorder which can present as an indolent or as an aggressive process involving skin, lymph nodes, and blood. In stages IA, IB and IIA, it is usually managed with topical medications and phototherapy. If there is progression despite application of these treatments, or if the patient presents with a higher stage of disease, systemic chemotherapy or retinoids, rexinoids, biologic response modifiers are often necessary. Consequently, patients are often treated with a sequence of modalities and drugs. Denileukin diftitox (DD, Ontak(R)) is a targeted immunotoxin which has biological activity against malignancies expressing the IL-2 receptor. In addition to its unique mechanism of action, DD has a toxicity profile which does not overlap with most commonly used chemotherapeutic agents. CTCL/MF has been found be particularly susceptible to treatment with this agent. This review will describe the development DD, its proposed mechanism of action, the clinical trials which identified its utility in the treatment of CTCL/MF, the common toxicities encountered with this agent, and the management of these toxicities. In addition the incorporation of DD in the sequential treatment of CTCL/MF and data suggesting potential combination therapies employing this novel agent will be discussed.
authors.affiliation: Division of Hematology/Oncology, New York University School of Medicine, New York, USA.
authors.forename: David
authors.initials: D
authors.lastname: Kaminetzky
authors.forename: Kenneth B
authors.initials: KB
authors.lastname: Hymes
references.citation: Eur J Cancer. 1997 Jan;33 Suppl 1:S34-6
references.pmid: 9166099
references.citation: Cytokine. 2004 Nov 7;28(3):109-23
references.pmid: 15473953
references.citation: J Clin Oncol. 2001 Jan 15;19(2):376-88
references.pmid: 11208829
references.citation: Blood. 2002 Aug 15;100(4):1399-403
references.pmid: 12149223
references.citation: J Am Acad Dermatol. 1998 Jul;39(1):63-73
references.pmid: 9674399
references.citation: Cancer Res. 1996 Jun 1;56(11):2590-5
references.pmid: 8653702
references.citation: J Clin Endocrinol Metab. 2006 Jun;91(6):2205-8
references.pmid: 16595600
references.citation: Arch Dermatol. 2007 Jul;143(7):854-9
references.pmid: 17638728
references.citation: Arch Dermatol. 2003 Jul;139(7):857-66
references.pmid: 12873880
references.citation: Clin Exp Dermatol. 2006 Mar;31(2):181-6
references.pmid: 16487086
references.citation: Br J Ophthalmol. 2006 Aug;90(8):1070-1
references.pmid: 16854841
references.citation: Leuk Res. 2002 Dec;26(12):1077-83
references.pmid: 12443879
references.citation: Semin Oncol Nurs. 2006 May;22(2):90-6
references.pmid: 16720231
references.citation: Leuk Lymphoma. 1993 Nov;11(5-6):369-77
references.pmid: 8124209
references.citation: Protein Eng. 1987 Dec;1(6):493-8
references.pmid: 3334101
references.citation: Blood. 1994 Sep 15;84(6):1765-74
references.pmid: 8080984
references.citation: Blood. 1998 Jan 15;91(2):399-405
references.pmid: 9427692
references.citation: Br J Dermatol. 2005 Aug;153(2):324-30
references.pmid: 16086743
references.citation: Am J Hematol. 1998 May;58(1):87-90
references.pmid: 9590158
references.citation: Clin Lymphoma. 2001 Mar;1(4):298-302
references.pmid: 11707845
references.citation: Blood. 2005 Jul 15;106(2):454-7
references.pmid: 15811959
references.citation: Cancer Res. 1989 Jul 15;49(14):4042-6
references.pmid: 2786749
references.citation: J Am Acad Dermatol. 1999 Mar;40(3):418-25
references.pmid: 10071312
references.citation: Blood. 2005 May 15;105(10):3768-85
references.pmid: 15692063
references.citation: J Clin Oncol. 1993 Sep;11(9):1682-90
references.pmid: 8355035
references.citation: J Biol Chem. 1990 Jul 15;265(20):11885-9
references.pmid: 2195027
references.citation: Hematology Am Soc Hematol Educ Program. 2006;:323-30, 513
references.pmid: 17124079
references.citation: Blood. 1992 May 15;79(10):2547-54
references.pmid: 1586707
references.citation: Haematologica. 2004 Nov;89(11):1372-88
references.pmid: 15531460
references.citation: J Exp Med. 1988 Feb 1;167(2):612-22
references.pmid: 3126255
references.citation: Br J Haematol. 2007 Aug;138(4):502-5
references.pmid: 17608763
references.citation: Cancer Res. 1993 Sep 1;53(17):3930-4
references.pmid: 8358720
references.citation: Semin Oncol. 2006 Feb;33(1 Suppl 3):S11-6
references.pmid: 16516670